Links

Tools

Export citation

Search in Google Scholar

Cost-effectiveness analysis of Daclatasvir/Sofosbuvir (DCV/SOF) for the treatment of the HCV patients failed after the first line with second generation of DAA in Italy.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Question mark in circle
Preprint: policy unknown
Question mark in circle
Postprint: policy unknown
Question mark in circle
Published version: policy unknown